Sunitinib and Capecitabine for First Line Colon Cancer

Inclusion Criteria:

Histologically confirmed, newly diagnosed metastatic colorectal cancer
Measurable or evaluable disease in which surgical resection with curative intent is not possible
No adjuvant chemotherapy within 6 months of enrollment
No prior sunitinib or other receptor tyrosine kinase inhibitors
18 years of age or greater
Anticipated survival of at least 6 months
Ambulatory with an ECOG performance status of 0 or 1 and able to maintain weight
Normal organ and marrow function
Must agree to avoid pregnancy or fathering a child through out study participation
Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

Chemotherapy or radiotherapy within 6 months of enrollment
Receiving any other investigational agents
Known untreated brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis
Not able to ingest oral medications with normal absorption from the GI tract
Uncontrolled hypertension
History of severe/unstable angina, heart attack, congestive heart failure, transient ischemic attack, or stroke within 6 months of enrollment
Cardiac dysrhythmias
History of clinically significant bleeding within the past 6 months, including gross hemoptysis or hematuria, or underlying coagulopathy
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study enrollment
Current treatment with therapeutic doses of coumadin
Concurrent malignancy other than colorectal cancer
Known dihydropyrimidine dehydrogenase deficiency
Uncontrolled intercurrent illness including ongoing or active infection or psychiatric illness that would limit compliance with study requirements.
Pregnant and nursing women